Management of anemia in chronic kidney disease patients

Baseline findings from Chronic Kidney Disease Japan Cohort Study

Tadao Akizawa, Hirofumi Makino, Seiichi Matsuo, Tsuyoshi Watanabe, Enyu Imai, Kosaku Nitta, Yasuo Ohashi, Akira Hishida

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.

Original languageEnglish
Pages (from-to)248-257
Number of pages10
JournalClinical and Experimental Nephrology
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 1 2011

Fingerprint

Chronic Renal Insufficiency
Hematinics
Anemia
Japan
Cohort Studies
Hemoglobins
Therapeutics
Dialysis
Maintenance
Prospective Studies
Guidelines

Keywords

  • Anemia
  • CKD
  • Erythropoiesis stimulating agent (ESA)
  • Hemoglobin (Hb)

ASJC Scopus subject areas

  • Nephrology
  • Physiology
  • Physiology (medical)

Cite this

Management of anemia in chronic kidney disease patients : Baseline findings from Chronic Kidney Disease Japan Cohort Study. / Akizawa, Tadao; Makino, Hirofumi; Matsuo, Seiichi; Watanabe, Tsuyoshi; Imai, Enyu; Nitta, Kosaku; Ohashi, Yasuo; Hishida, Akira.

In: Clinical and Experimental Nephrology, Vol. 15, No. 2, 01.04.2011, p. 248-257.

Research output: Contribution to journalArticle

Akizawa, Tadao ; Makino, Hirofumi ; Matsuo, Seiichi ; Watanabe, Tsuyoshi ; Imai, Enyu ; Nitta, Kosaku ; Ohashi, Yasuo ; Hishida, Akira. / Management of anemia in chronic kidney disease patients : Baseline findings from Chronic Kidney Disease Japan Cohort Study. In: Clinical and Experimental Nephrology. 2011 ; Vol. 15, No. 2. pp. 248-257.
@article{6fc9db60c02f46f89d20ddc348b03c5a,
title = "Management of anemia in chronic kidney disease patients: Baseline findings from Chronic Kidney Disease Japan Cohort Study",
abstract = "Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6{\%}, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7{\%}, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.",
keywords = "Anemia, CKD, Erythropoiesis stimulating agent (ESA), Hemoglobin (Hb)",
author = "Tadao Akizawa and Hirofumi Makino and Seiichi Matsuo and Tsuyoshi Watanabe and Enyu Imai and Kosaku Nitta and Yasuo Ohashi and Akira Hishida",
year = "2011",
month = "4",
day = "1",
doi = "10.1007/s10157-010-0396-7",
language = "English",
volume = "15",
pages = "248--257",
journal = "Clinical and Experimental Nephrology",
issn = "1342-1751",
publisher = "Springer Japan",
number = "2",

}

TY - JOUR

T1 - Management of anemia in chronic kidney disease patients

T2 - Baseline findings from Chronic Kidney Disease Japan Cohort Study

AU - Akizawa, Tadao

AU - Makino, Hirofumi

AU - Matsuo, Seiichi

AU - Watanabe, Tsuyoshi

AU - Imai, Enyu

AU - Nitta, Kosaku

AU - Ohashi, Yasuo

AU - Hishida, Akira

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.

AB - Background: Anemia is a factor that affects the outcome of patients with chronic kidney disease (CKD); however, there are only a few reports on the management of anemia in Japanese patients with CKD who are not on dialysis. Methods: We investigated the prevalence, related factors and management of anemia in CKD stage 3-5 patients in Japan based on the baseline data obtained from a prospective cohort study (Chronic Kidney Disease Japan Cohort). Anemia was defined as having a hemoglobin (Hb) level of <11 g/dL or receiving erythropoiesis stimulating agent (ESA) therapy. Results: The result indicated that 946 out of 2,930 patients had anemia. Of these 946 patients, 385 were receiving ESA treatment for anemia and had an Hb level of 10.28 ± 1.19 g/dL (mean ± SD). The percentage of these patients with an Hb level above the target of 11 g/dL proposed for treatment by the Japanese guidelines, and above the maintenance level of 10 g/dL approved for ESA therapy in Japan, was only 30.1 and 61.6%, respectively. In contrast, the percentage of patients receiving no ESA therapy was 67.6 and 55.7%, respectively, among those with an Hb level of <11 and <10 g/dL. Conclusions: These data suggested that prevalence of anemia was high in Japanese patients with CKD stage 3-5, that the percentage of patients receiving ESA was low among those who required ESA, and that a large number of patients receiving ESA failed to maintain the recommended level of Hb.

KW - Anemia

KW - CKD

KW - Erythropoiesis stimulating agent (ESA)

KW - Hemoglobin (Hb)

UR - http://www.scopus.com/inward/record.url?scp=79959233106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959233106&partnerID=8YFLogxK

U2 - 10.1007/s10157-010-0396-7

DO - 10.1007/s10157-010-0396-7

M3 - Article

VL - 15

SP - 248

EP - 257

JO - Clinical and Experimental Nephrology

JF - Clinical and Experimental Nephrology

SN - 1342-1751

IS - 2

ER -